STOCK TITAN

EDAP TMS S.A. - EDAP STOCK NEWS

Welcome to our dedicated news page for EDAP TMS S.A. (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on EDAP TMS S.A..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EDAP TMS S.A.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EDAP TMS S.A.'s position in the market.

Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) announced unaudited financial results for Q1 2023, with total revenue of EUR 14.8 million, a 13.8% increase compared to Q1 2022. The HIFU business revenue increased by 39.5% driven by the sale of six Focal One units. The LITHO business revenue improved due to the sale of four lithotripsy units. The Distribution business revenue decreased slightly. Gross profit margin was 40.8%, lower than the previous year due to investments in service and applications in the U.S. Operating expenses increased significantly to EUR 12.6 million, mainly due to the ongoing build-out of the U.S. team and non-recurring expenses related to the leadership succession plan. The company reported an operating loss of EUR 6.6 million and a net loss of EUR 7.5 million. Cash and cash equivalents were EUR 58.3 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
EDAP TMS S.A.

Nasdaq:EDAP

EDAP Rankings

EDAP Stock Data

280.88M
29.56M
43.11%
0.28%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
France
Lyon

About EDAP

global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke